Brainsway (BWAY) Upgraded to Buy: Here's Why
Brainsway (BWAY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks Investment Research8/17/2026Positive
BWAY
Brainsway LtdNASDAQHEALTHCAREMEDICAL DEVICES
Key Statistics
Market Cap
$621.63M
P/E Ratio
70.41
EPS
$0.22
Beta
0.10
52W High
$17.40
52W Low
$7.13
50-Day MA
$15.13
200-Day MA
$12.78
Dividend Yield
—
Profit Margin
15.60%
Forward P/E
38.91
PEG Ratio
—
About Brainsway Ltd
Brainsway Ltd., a commercial-stage medical device company, focuses on the development and sale of non-invasive neuromodulation products in Israel and internationally. The company is headquartered in Jerusalem, Israel.
Fundamentals
| Revenue (TTM) | $60.70M |
| Gross Profit (TTM) | $45.72M |
| EBITDA | $8.48M |
| Operating Margin | 14.00% |
| Return on Equity | 12.80% |
| Return on Assets | 4.05% |
| Revenue/Share (TTM) | $1.61 |
| Book Value | $2.04 |
| Price-to-Book | 8.27 |
| Price-to-Sales (TTM) | 10.24 |
| EV/Revenue | 9.89 |
| EV/EBITDA | 50.44 |
| Quarterly Earnings Growth (YoY) | 64.60% |
| Quarterly Revenue Growth (YoY) | 35.40% |
| Shares Outstanding | $40.13M |
| Float | $23.20M |
| % Insiders | 6.03% |
| % Institutions | 29.06% |
Historical Volatility
HV 10-Day
71.93%
HV 20-Day
69.06%
HV 30-Day
67.37%
HV 60-Day
56.52%
HV Rank
99.6%
Volatility is currently expanding
Analyst Ratings
Consensus ($18.60 target)
3
BuyLatest News
Brainsway Q2 Earnings Call Highlights
Brainsway NASDAQ: BWAY reported second-quarter revenue growth of 35% and raised its full-year 2026 revenue outlook, citing continued demand for its Deep TMS systems, expanding reimbursement for its accelerated SWIFT treatment protocol and growth in its installed base.
MarketBeat8/13/2026Positive
BrainsWay Ltd. (BWAY) Q2 2026 Earnings Call Transcript
BrainsWay Ltd. (BWAY) Q2 2026 Earnings Call Transcript
Seeking Alpha8/12/2026Neutral
BrainsWay Reports Second Quarter 2026 Financial Results and Operational Highlights
Record s econd q uarter 2026 r evenue increased 35% t o $17. 1 m illion, compared with Q2 2025
GlobeNewsWire8/12/2026Neutral
BrainsWay: Building A Capital-Light Interventional Psychiatry Ecosystem
BrainsWay is transitioning from a device manufacturer to a capital-light ecosystem provider for interventional psychiatry, leveraging recurring revenue and minority investments. BWAY reported Q1-2026 revenue up 35% YoY, a steady 75% gross margin, and expects FY-2026 revenue of $66–68M with adjusted EBITDA growth of 86–100%. Multi-year leasing, accelerated protocols, and expanded provider access are reducing TMS adoption barriers, supporting higher utilization and stickier customer relationships.
Seeking Alpha8/6/2026Positive
Brainsway (BWAY) is on the Move, Here's Why the Trend Could be Sustainable
Brainsway (BWAY) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Zacks Investment Research7/22/2026Positive
4 Medical Products Stocks Poised to Win Despite Industry Headwinds
Terumo, QuidelOrtho, Lumexa Imaging and BrainsWay are tackling industry headwinds through innovation, pricing and execution as healthcare demand stays resilient.
Zacks Investment Research7/20/2026Neutral
BrainsWay Announces Strategic Investment in Radial Health, Inc.
BrainsWay continues to actively evaluate similar investments in leading North American mental health providers to raise awareness and expand access to transformative care BrainsWay continues to actively evaluate similar investments in leading North American mental health providers to raise awareness and expand access to transformative care
GlobeNewsWire7/20/2026Neutral
BrainsWay Announces Minority-Stake Investment in Sound Minds Behavioral
Investment further supports BrainsWay's strategy of partnering with growth-oriented mental health providers to raise awareness and expand access to transformative care Investment further supports BrainsWay's strategy of partnering with growth-oriented mental health providers to raise awareness and expand access to transformative care
GlobeNewsWire7/16/2026Neutral
Best Momentum Stocks to Buy for July 14th
BWAY, HTLD and NCNO made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 14th, 2026.
Zacks Investment Research7/14/2026Positive
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on BWAY and any ticker you trade — then tracks every position and per-strategy win rate.
More HEALTHCARE Stocks
Data last updated: 8/18/2026